Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives

// Jonathan M. Lehman 1 , 2 , 3 and Pierre P. aMassion 1 , 2 , 3 1 Division of Medical Oncology, Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA 2 Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA 3 Veterans Affairs, Tennessee Valley Healthcare System, Nashville Campus, Nashville, TN, USA Correspondence to: Jonathan M. Lehman, email: jonathan.m.lehman@vanderbilt.edu Keywords: small cell lung cancer; somatostatin receptor 2; antibody-drug conjugate; peptide drug conjugate; perspectives Received: June 18, 2019     Accepted: June 29, 2019     Published: July 30, 2019 ABSTRACT Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as a viable target for SCLC, summarize the current clinical trial space, and describe promising new research and clinical directions for Somatostatin Receptor 2 targeting in SCLC.